Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 19/20 | 1.00 |
| ▸ | F2 | P00734 | 17/20 | 1.00 |
| ▸ | F9 | P00740 | 2/20 | 0.79 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367326 | 0.88 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL6616732 | 0.88 | F10 (0.78) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7365282 | 0.84 | F10 (0.81) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7438126 | 0.78 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7449310 | 0.76 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7366733 | 0.75 | F10 (0.75) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL6613306 | 0.72 | F2 (0.56) | F10PRSS1F2F9 | |
| SCHEMBL7438119 | 0.69 | F10 (0.66) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7368198 | 0.69 | F2 (0.59) | F10PRSS1F2F9 | |
| SCHEMBL8019753 | 0.68 | F10 (0.66) | F10PRSS1F2F9PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362062-B2 | Pharmaceutical compositions with improved dissolution | MCNEIL-PPC, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2339328-A2 | Pharmaceutical co-crystal compositions of celecoxib | Transform Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | JOHNSON & JOHNSON CONSUMER INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20050112197-A1 | Stabilized oral pharmaceutical composition | GAO PING (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1515703-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1494666-A1 | ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (COX-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT | Pharmacia Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004000284-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030105144-A1 | Stabilized oral pharmaceutical composition | PHARMACIA CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PHARMACIA CORPORATION | 2003-05-29 | — | — | US | disclosed |
| WO-2002102376-A1 | ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT | PHARMACIA CORPORATION (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | F10 49/4885PRSS1 770/4885F2 270/4885 |
| US-20030100595-A1 | Oral dosage form of a sulfonamide prodrug | PTGS2, PTGES2, SI | F10 1491/4885PRSS1 20/4885F2 184/4885 |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | F10 46/4885PRSS1 640/4885F2 193/4885 |
| US-20030105144-A1 | Stabilized oral pharmaceutical composition | PTGS2, PTGES2, PTGES | F10 1250/4885PRSS1 290/4885F2 441/4885 |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | F10 46/4885PRSS1 640/4885F2 193/4885 |
| US-20050112197-A1 | Stabilized oral pharmaceutical composition | PTGS2, PTGES2, PTGES | F10 1250/4885PRSS1 290/4885F2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.